Time to confirmed disability worsening was longer in patients who received dimethyl fumarate, compared with those who received teriflunomide, in an analysis of real-world data.
The new anti-CD20 monoclonal antibody showed significant improvement in the multiple sclerosis functional composite (MSFC) score, a measure of disability, compared with teriflunomide.
Rituximab reduced relapses and MRI activity more effectively than dimethyl fumarate, natalizumab, and injectable therapies in a recent study. Disability did not differ between treatments, however.
New data on COVID vaccination in MS patients has shown a reduced humoral response in patients treated with certain medications including ocrelizumab, rituximab, and fingolimod but not others.